Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT03112603
- Locations
- 🇵🇷
Incyte Investigative Site, Ponce, Puerto Rico
🇬🇧Novartis Investigative Site, Manchester, United Kingdom
🇷🇴Novartis Investigational Site, Bucharest, Romania
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03069326
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT03041636
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Conditions
- Recurrent Adult Acute Myeloid LeukemiaRecurrent Anaplastic Large Cell LymphomaB-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic SyndromeRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Plasma Cell MyelomaPreviously Treated Myelodysplastic SyndromeRecurrent T-Cell Non-Hodgkin LymphomaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Positron Emission TomographyDrug: CyclophosphamideBiological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide SymporterProcedure: Single Photon Emission Computed TomographyDrug: RuxolitinibBiological: Cemiplimab
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT03017820
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT02974647
- Locations
- 🇺🇸
Northwestern Medicine (Data collection and specimen analysis), Chicago, Illinois, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT02973711
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.
- Conditions
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT02966353
- Locations
- 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT02955940
- Locations
- 🇺🇸
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
🇺🇸New York Oncology Hematology Pc., Clifton Park, New York, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT02953678
Ruxolitinib for Premalignant Breast Disease
- Conditions
- Interventions
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Julie Nangia
- Target Recruit Count
- 100
- Registration Number
- NCT02928978
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.